

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

VOLUNTARY ANNOUNCEMENT

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

Reference is made to the announcement of the Company dated January 26, 2024 (the “**Announcement**”) in relation to, among other things, WuXi AppTec being named in a draft bill version of the Biosecure Act (the “**Draft Bill**”) introduced to the U.S. House of Representatives on January 25, 2024. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As stated in the Announcement, the Company noted that the Draft Bill contained certain alleged findings with respect to WuXi AppTec which we believe are neither legitimate nor accurate. In connection with such alleged findings, the Company is of the view that (i) the Company is confident that the business of WuXi AppTec will not pose a national security risk to any country; (ii) the Company has never sponsored any military-civil fusion themed conference or other events; (iii) the Company has never received any direct investment from military-civil fusion funds, and as a publicly listed company in Shanghai and Hong Kong, there are over two hundred thousand institutional and individual investors investing and trading in the shares of the Company on the secondary market globally with the Company receiving no investment funds from these secondary market investors; and (iv) in order to promote the technological advancement and development in chemistry, life sciences, medicine, pharmacy and related fields, WuXi AppTec has established the “WuXi AppTec Life Chemistry Research Award” back in 2007, which has aimed to reward outstanding young and middle-aged scientific and technological talents having achieved significant results or made exceptional contributions in scientific research, technological innovation and invention in chemistry, life sciences, medicine and pharmacy related technological fields. The objective selection criteria of this award are only related to relevant scientific research experience, scientific research capabilities and scientific research results, and no special consideration has been given to the background or affiliation of any candidate.

As at the date of this announcement, the production and operational activities of the Company remain normal, and there are no material changes to the daily operations of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, January 29, 2024

As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*